Related Experiment Video
Updated: Jun 20, 2026
10:13
Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
Published on: February 14, 2014
Dehydroepiandrosterone and age-related cognitive decline
Krystina G Sorwell1, Henryk F Urbanski
1Oregon National Primate Research Center, Beaverton, OR 97006, USA.
Age (Dordrecht, Netherlands)
|August 28, 2009
Summary
Dehydroepiandrosterone (DHEA) levels decline with age, impacting cognition. While DHEA supplementation shows promise in rodents for cognitive anti-aging, its efficacy in humans is limited, suggesting differences in aging pathways and the need for better animal models.
Area of Science:
- Neuroscience
- Endocrinology
- Aging Research
Background:
- Circulating dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS) concentrations decrease significantly with aging in humans.
- These age-related hormonal changes are linked to cognitive decline, prompting research into DHEA supplementation for memory improvement.
- Rodent studies suggest DHEA/DHEAS possess cognitive anti-aging effects, but the mechanism, particularly the role of estradiol conversion, remains unclear.
Purpose of the Study:
- To review the role of DHEA and DHEAS in age-associated cognitive decline.
- To investigate the efficacy of DHEA supplementation as a cognitive anti-aging therapy in humans.
- To evaluate the suitability of nonhuman primates as an animal model for studying DHEA's therapeutic potential in humans.
Main Methods:
- Review of existing literature on DHEA, DHEAS, aging, and cognitive function.
- Comparative analysis of DHEA/DHEAS concentrations and metabolic pathways in rodents, nonhuman primates, and humans.
- Discussion of the potential reasons for the limited efficacy of DHEA replacement therapies in humans.
Main Results:
- Significant differences exist in circulating DHEA and DHEAS levels between rodents and primates during aging.
- Age-related alterations in the human DHEA metabolic pathway may explain the reduced effectiveness of DHEA supplementation in humans.
- Correlations between endogenous DHEA and cognitive ability are not consistently observed in normally aging humans.
Conclusions:
- The efficacy of DHEA supplementation for age-associated cognitive decline may be limited in humans due to species-specific metabolic differences.
- Nonhuman primates represent a valuable model for investigating the therapeutic potential of DHEA for human cognitive aging.
- Further research is needed to elucidate the complex relationship between DHEA, aging, and cognitive function across species.
More Related Videos
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
14:57Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Aging
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...